Drugmaker Lilly's 2016 forecast misses Street expectations


The drugmaker says it expects adjusted earnings in the new year to range between $3.45 and $3.55 per share, excluding charges like deal integration costs. It predicts revenue of between $20.2 billion and $20.7 billion.



from Biotech News